Cizzle Biotechnology Holdings PLC Cash Flow Conversion Efficiency

Latest as of June 2025: 1.199x

Cizzle Biotechnology Holdings PLC cash flow conversion efficiency. Based on the latest financial reports, Cizzle Biotechnology Holdings PLC (CIZ) has a cash flow conversion efficiency ratio of 1.199x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-331.00K ≈ $-40.27 USD) by net assets (GBX-276.00K ≈ $-33.58 USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Cizzle Biotechnology Holdings PLC (2006–2024)

Cash flow conversion efficiency of Cizzle Biotechnology Holdings PLC from 2006 to 2024. This chart illustrates how Cizzle Biotechnology Holdings PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Cizzle Biotechnology Holdings PLC share price for real-time trading data and today's change.

Cizzle Biotechnology Holdings PLC Cash Flow Conversion Ratio Explained

Cizzle Biotechnology Holdings PLC cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Cizzle Biotechnology Holdings PLC Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Cizzle Biotechnology Holdings PLC ranked by their cash flow conversion efficiency. Also see CIZ stock market capitalisation for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Nanoco Group plc
LSE:NANO
-0.051x
Image Scan Holdings Plc
LSE:IGE
-0.246x
GOLCAP RESOURCES CORP
F:2SO0
-0.030x
Trakm8 Holdings PLC
LSE:TRAK
-0.013x
MyHealthChecked Plc
LSE:MHC
-0.067x
Selina Hospitality PLC
NASDAQ:SLNAF
-0.016x
Northann Corp.
NYSE MKT:NCLX
-0.076x
Sporttotal AG
F:WIG1
0.078x

Annual Cash Flow Conversion Efficiency for Cizzle Biotechnology Holdings PLC (2006–2024)

The table below shows the annual cash flow conversion efficiency of Cizzle Biotechnology Holdings PLC from 2006 to 2024. Review Cizzle Biotechnology Holdings PLC (CIZ) free cash flow to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 GBX82.00K
≈ $9.98
GBX-358.00K
≈ $-43.56
-4.366x -929.63%
2023-12-31 GBX1.51 Million
≈ $183.36
GBX-639.00K
≈ $-77.75
-0.424x -28.37%
2022-12-31 GBX2.64 Million
≈ $321.21
GBX-872.00K
≈ $-106.10
-0.330x +69.33%
2021-12-31 GBX937.00K
≈ $114.01
GBX-1.01 Million
≈ $-122.77
-1.077x +88.28%
2020-12-31 GBX32.00K
≈ $3.89
GBX-294.00K
≈ $-35.77
-9.188x -761.46%
2019-12-31 GBX6.63K
≈ $0.81
GBX-7.07K
≈ $-0.86
-1.067x -148.86%
2018-12-31 GBX-235.00K
≈ $-28.59
GBX-513.00K
≈ $-62.42
2.183x +951.36%
2017-12-31 GBX741.00K
≈ $90.16
GBX-190.00K
≈ $-23.12
-0.256x -401.49%
2016-12-31 GBX2.19 Million
≈ $266.09
GBX186.00K
≈ $22.63
0.085x +135.88%
2015-12-31 GBX2.40 Million
≈ $292.62
GBX-570.00K
≈ $-69.35
-0.237x -127.41%
2014-12-31 GBX5.05 Million
≈ $614.07
GBX-526.00K
≈ $-64.00
-0.104x +34.38%
2013-12-31 GBX4.27 Million
≈ $519.41
GBX-678.00K
≈ $-82.49
-0.159x -424.98%
2012-12-31 GBX4.79 Million
≈ $583.17
GBX-145.00K
≈ $-17.64
-0.030x +91.82%
2011-12-31 GBX4.08 Million
≈ $496.90
GBX-1.51 Million
≈ $-183.72
-0.370x -329.38%
2010-12-31 GBX3.54 Million
≈ $430.96
GBX-305.00K
≈ $-37.11
-0.086x +70.09%
2009-12-31 GBX521.00K
≈ $63.39
GBX-150.00K
≈ $-18.25
-0.288x +69.03%
2008-12-31 GBX1.67 Million
≈ $202.70
GBX-1.55 Million
≈ $-188.47
-0.930x -6.47%
2007-12-31 GBX2.40 Million
≈ $291.89
GBX-2.10 Million
≈ $-254.90
-0.873x -104.62%
2006-12-31 GBX-58.00K
≈ $-7.06
GBX-1.10 Million
≈ $-133.47
18.914x --

About Cizzle Biotechnology Holdings PLC

LSE:CIZ UK Biotechnology
Market Cap
$55.46K
GBX455.85 Million GBX
Market Cap Rank
#31656 Global
#1186 in UK
Share Price
GBX1.15
Change (1 day)
+0.00%
52-Week Range
GBX1.03 - GBX3.65
All Time High
GBX1144.91
About

Cizzle Biotechnology Holdings Plc, together with its subsidiaries, operates as a cancer diagnostics company in the United Kingdom. It develops a non-invasive blood test for early lung cancer detection using CIZ1B biomarker technology. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings … Read more